Literature DB >> 18568312

Cardiomyopathy in type 2 diabetes: update on pathophysiological mechanisms.

Justin Saunders1, Shiny Mathewkutty, Mark H Drazner, Darren K McGuire.   

Abstract

Type 2 diabetes mellitus (DM) is associated with increased risk for developing heart failure (HF) and worse outcomes once HF is present. While the exact mechanisms underpinning these observations remain poorly understood, several metabolic perturbations associated with DM have been implicated as contributors to the HF risk, including alterations of cardiomyocyte metabolic substrate switching between free fatty acid (FFA) and glucose metabolism; increased FFA exposure and cellular accumulation; and alterations in peroxisome proliferator-activated receptor-(PPAR-)alpha activity, among others. The commonly coincident conditions of left ventricular hypertrophy and ischemic heart disease likely confound the metabolic derangements further increasing HF risk. Continued investigation into these mechanistic connections is necessary to better understand the pathophysiology and ideally inform the pursuit of novel therapeutic targets and strategies to intervene on the HF associated with DM.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18568312     DOI: 10.1007/s00059-008-3115-3

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  17 in total

1.  [Cardiac rehabilitation--more than just for the garden plot?].

Authors:  B Maisch
Journal:  Herz       Date:  2012-02       Impact factor: 1.443

Review 2.  Treatment strategies for the prevention of heart failure.

Authors:  Justin L Grodin; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2013-12

Review 3.  Catheter ablation in atrial fibrillation: is there a mortality benefit in patients with diabetes and heart failure?

Authors:  M Matta; A Saglietto; P De Salvo; A Bissolino; A Ballatore; M Anselmino
Journal:  Herz       Date:  2019-05       Impact factor: 1.443

Review 4.  Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications.

Authors:  C A Alvarez; I Lingvay; V Vuylsteke; R L Koffarnus; D K McGuire
Journal:  Clin Pharmacol Ther       Date:  2015-07-03       Impact factor: 6.875

Review 5.  Diabetic cardiomyopathy: signaling defects and therapeutic approaches.

Authors:  Joseph S Dobrin; Djamel Lebeche
Journal:  Expert Rev Cardiovasc Ther       Date:  2010-03

6.  Apigenin alleviates STZ-induced diabetic cardiomyopathy.

Authors:  Huang-Jun Liu; Yun-Lin Fan; Hai-Han Liao; Yuan Liu; Si Chen; Zhen-Guo Ma; Ning Zhang; Zheng Yang; Wei Deng; Qi-Zhu Tang
Journal:  Mol Cell Biochem       Date:  2017-02-07       Impact factor: 3.396

7.  A patient with Graves' disease who survived despite developing thyroid storm and lactic acidosis.

Authors:  Tetsuhiro Yoshino; Daisuke Kawano; Takeo Azuhata; Tsukasa Kuwana; Rikimaru Kogawa; Atsushi Sakurai; Katsuhisa Tanjoh; Tatsuo Yanagawa
Journal:  Ups J Med Sci       Date:  2010-08-23       Impact factor: 2.384

8.  Diabetes and heart failure in patients with coronary disease: separating markers from mediators.

Authors:  Darren K McGuire; M Odette Gore; Frederick A Masoudi
Journal:  Diabetes Care       Date:  2010-09       Impact factor: 17.152

9.  SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states.

Authors:  Sanjay K Banerjee; Kenneth R McGaffin; Núria M Pastor-Soler; Ferhaan Ahmad
Journal:  Cardiovasc Res       Date:  2009-06-09       Impact factor: 10.787

10.  Lipotoxicity-mediated cell dysfunction and death involve lysosomal membrane permeabilization and cathepsin L activity.

Authors:  Frankis G Almaguel; Jo-Wen Liu; Fabio J Pacheco; Daisy De Leon; Carlos A Casiano; Marino De Leon
Journal:  Brain Res       Date:  2010-01-04       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.